Patents by Inventor Sharon Lea Aukerman
Sharon Lea Aukerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20150086991Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: ApplicationFiled: November 25, 2014Publication date: March 26, 2015Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AGInventors: Sharon Lea Aukerman, Mohammad Luqman
-
Patent number: 8926979Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: GrantFiled: November 1, 2006Date of Patent: January 6, 2015Assignees: Novartis AG, XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Publication number: 20130230528Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: ApplicationFiled: December 17, 2012Publication date: September 5, 2013Applicants: XOMA TECHNOLOGY LTD., NOVARTIS AGInventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Publication number: 20130011405Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: September 12, 2012Publication date: January 10, 2013Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
-
Patent number: 8337851Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: GrantFiled: May 18, 2006Date of Patent: December 25, 2012Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Patent number: 8333970Abstract: Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: GrantFiled: May 18, 2006Date of Patent: December 18, 2012Assignees: Novartis AG, Xoma Technology Ltd.Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Publication number: 20100017895Abstract: An animal model for HCV replication and/or production of virus or virus like particles is provided. The invention utilizes an HCV replicon present in a cell to deliver HCV nucleic acid and replicate and express HCV proteins in an animal model comprising an animal that has been immunocompromised. The invention further provides a method of treatment or prevention of HCV in a mammal which comprises administering to the mammal a combination which comprises an immunomodulatory compound and another antiviral agent. Also provided are cell lines showing a decreased sensitivity to interferon alpha or some other immunomodulator and methods of making or isolating such cell lines.Type: ApplicationFiled: July 15, 2006Publication date: January 21, 2010Inventors: Amy Weiner, Sharon Lea Aukerman, Dirk Mendel, Qing Zhu
-
Publication number: 20090202531Abstract: Methods for treating a human patient for an inflammatory or autoimmune disease that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with an inflammatory or autoimmune disease that is treatable with an anti-CD40 antibody and which is non-responsive or refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having an inflammatory or autoimmune disease that is non-responsive or refractory to treatment with rituximab (Rituxan®), are also provided.Type: ApplicationFiled: November 1, 2006Publication date: August 13, 2009Applicants: Novartis AG, XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Publication number: 20090117111Abstract: Methods for treating a human patient for a cancer or pre-malignant condition that is associated with CD40-expressing cells are provided, where the human patient is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). Also provided are methods of inhibiting antibody production by B cells in a human patient who is heterozygous or homozygous for Fc?RIIIa-158F (genotype V/F or F/F). The methods comprise administering to the human patient a therapeutically or prophylactically effective amount of an anti-CD40 antibody. Methods and kits for identifying a human patient with a cancer or pre-malignant condition that is treatable with an anti-CD40 antibody and which is refractory to treatment with rituximab (Rituxan®), as well as methods and kits for selecting an antibody therapy for treatment of a human patient having a cancer or pre-malignant condition that is refractory to treatment with rituximab (Rituxan®), are also provided.Type: ApplicationFiled: November 1, 2006Publication date: May 7, 2009Inventors: Sharon Lea Aukerman, Mohammad Luqman
-
Publication number: 20090041773Abstract: Methods for identifying subjects having a cancer or pre-malignant condition that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing neoplastic cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: ApplicationFiled: May 18, 2006Publication date: February 12, 2009Applicants: Novartis Vaccines and Diagnostics , Inc., XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Publication number: 20080274118Abstract: Methods for identifying subjects having an inflammatory disease and/or autoimmune disease that will benefit from anti-CD40 therapeutic agents that modulate CD40L-mediated CD40 signaling are provided. The methods comprise the use of biomarkers of cellular apoptosis, cell proliferation and survival, and CD40 signaling pathways to monitor ex vivo response to one or more anti-CD40 therapeutic agents of interest that modulate CD40 signaling on CD40-expressing cells. The ex vivo prognostic assays can be used alone or in conjunction with other prognostic assays to identify candidate subjects who will benefit from treatment with anti-CD40 therapeutic agents. Methods of the invention also comprise the use of these biomarkers to monitor in vivo efficacy of treatment with an anti-CD40 therapeutic agent.Type: ApplicationFiled: May 18, 2006Publication date: November 6, 2008Applicants: Novartis Vaccines and Diagnostics, Inc., XOMA Technology Ltd.Inventors: Sharon Lea Aukerman, Bahija Jallal, Mohammad Luqman
-
Publication number: 20080254026Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.Type: ApplicationFiled: October 31, 2007Publication date: October 16, 2008Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Bao-Lu Chen, Xiaofeng Lu, Sang Hoon Lee, Deborah Hurst, Sharon Lea Aukerman, Daniel E. Lopes de Menezes
-
Patent number: 5858977Abstract: A method and pharmaceutical compositions are described for the use of keratinocyte growth factor to treat diabetes mellitus in mammals.Type: GrantFiled: April 11, 1997Date of Patent: January 12, 1999Assignee: Amgen Inc.Inventors: Sharon Lea Aukerman, Glenn Francis Pierce
-
Patent number: 5725850Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.Type: GrantFiled: January 11, 1995Date of Patent: March 10, 1998Assignee: Chiron CorporationInventors: Peter Ralph, Kong T. Chong, James Devlin, Robert Zimmerman, Sharon Lea Aukerman, David B. Ring, Sylvia Hsieh Ma